69 results about "Ischemic myocardium" patented technology

The invention provides, among other things, methods for treating an ischemic tissue in a subject in need thereof. The invention further provides methods for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides cell-based formulations and related kits.

Methods and apparatus for preventing myocardial infarction, or lessening the size / severity of an evolving myocardial infarction, by cooling at least the affected area of the myocardium using an intravascular heat exchange catheter. The heat exchange catheter may be inserted into the vasculature (e.g., a vein) and advanced to a position wherein a heat exchanger on the catheter is located in or near the heart (e.g., within the vena cava near the patient's heart). Thereafter, the heat exchange catheter is used to cool the myocardium (or the entire body of the patient) to a temperature that effectively lessens the metabolic rate and / or oxygen consumption of the ischemic myocardial cells or otherwise protects the ischemic myocardium from undergoing irreversible damage or infarction.

The invention discloses a use of a derived polypeptide series of pigment epithelium derived factors in ischemic myocardium protection. The polypeptide is derived from the pigment epithelium derived factors, and every amino acid sequence in the polypeptide includes at least eighteen continuous amino acid residues. The PEDF derived functional peptide has good function advantages, and has remarkablecardiac muscle tissue capillary tube stabilization, vascular leakage prevention, myocardial cell protection and cardiac muscle tissue inflammation prevention effects.

The invention discloses a preparation method and application of a pyridazinone myocardial perfusion PET radiopharmaceutical. According to the invention, a large-dose initial 18F activity label is adopted, the precursor usage amount of a reaction, the reaction temperature and the purification HPLC condition are optimized, the reaction yield is improved, the preparation amount of [18F]Fmpp2 can reach 200 mCi, the chemical impurity amount is reduced, the radiochemical purity is high, and the key quality index is kept stable within 6 hours. A method for preparing a [18F]Fmpp2 solution for injection is improved, and the radiochemical purity and stability of the [18F]Fmpp2 are improved. The [18F]Fmpp2 prepared by the invention is subjected to miniature pig myocardial model PET imaging display; after the [18F]Fmpp2 is intravenously injected, the myocardial radioactive uptake is high, and the influence of peripheral organs on myocardial development is small; and normal myocardium, ischemic myocardium caused by chronic coronary artery stenosis and infarcted myocardium caused by acute coronary artery stenosis can be distinguished.

The invention provides, among other things, methods and systems for expanding CD133+ cells. The invention further provides methods and systems for increasing the blood flow to an ischemic tissue in a subject in need thereof, such as to ischemic myocardium. The invention further provides methods and systems for directing differentiation of expanded CD133+ cells. The invention further provides methods and systems for treating a subject with differentiated cells in a subject in need thereof.

The invention relates to a focusing ultrasonic cavitation treatment instrument which is used for treating tumor, thrombolysis, ischemic myocardium and disease of prostate based on the cavitation effect of the ultrasonic contrast agent microvesicle. The focusing ultrasonic cavitation treatment instrument comprises a main control machine, two combined treatment probes, and a B ultrasonic machine with an ultrasonic focusing ultrasonic cavitation treatment instrument function. The focusing ultrasonic cavitation treatment instrument is mainly used for the partial area of the focus, and carries out non-invasive treatment on the tumor based on the cavitation effect of the microvesicle. The microvesicle can greatly improve the cavitation effect, so that the ultrasonic focusing positioning radiation with low power can be precisely carried out in the partial area of the focus, and the cavitation effect of the microvesicle within the vessel just can be activated within the partial area, and the capillaries in the tumor can be subject to embolism and damage, so as to achieve the purpose of 'starving' the tumor. The threshold for generating the cavitation is not met by the ultrasonic energy at the periphery of the focusing area, so that the cavitation effect is not generated, so that the path where the ultrasonic wave passes or the ambient tissue can not be damaged; and the functions of the common tissue and organs are protected.

The invention discloses a transmural myocardial revascularization biodegradable drug controlled-release bracket and a preparation method thereof. The transmural myocardial revascularization biodegradable drug controlled-release bracket comprises a hollow tube with the inner diameter of 0.2mm to 1mm, the wall thickness of 0.1 to 0.5mm and the length of 0.1 to 0.5mm, the wall of the tube is provided with a hole that runs through the wall, and the material of the tube is biodegradable polymer that is loaded with cell growth factors and / or heparin. The bracket of the invention can prevent the hole channel of transmural myocardial revascularization (TMR) from closing and keep the blood flow perfusion unobstructed; the bracket can be degraded into micro molecules to be excreted to the outside of the body shortly after the supporting function and drug-controlling function are completed, thus avoiding adverse impact caused by staying in the body for a long time; the drug controlled-release growth factors can promote the revascularization and the heparin has the function of anticoagulation, thus being beneficial to the restoration of partial ischemic myocardium.

Methods and apparatus for preventing myocardial infarction, or lessening the size / severity of an evolving myocardial infarction, by cooling at least the affected area of the myocardium using an intravascular heat exchange catheter. The heat exchange catheter may be inserted into the vasculature (e.g., a vein) and advanced to a position wherein a heat exchanger on the catheter is located in or near the heart (e.g., within the vena cava near the patient's heart). Thereafter, the heat exchange catheter is used to cool the myocardium (or the entire body of the patient) to a temperature that effectively lessens the metabolic rate and / or oxygen consumption of the ischemic myocardial cells or otherwise protects the ischemic myocardium from undergoing irreversible damage or infarction.

The invention discloses a VEGF165 and Ang-1 double-gene co-expression vector. The double-gene co-expression vector contains a human gene VEGF165 and a human Ang-1 gene; the double-gene co-expression vector is pAdTrack-CMV-Ang-1-IRES-VEGF165; the double genes are recombined to transfer vectors; the double genes are in homologous recombination with the adenovirus framework plasmid pAdEasy-1 and then are packed and augmented in QB 1-293A cells so as to obtain an Ad-Ang-1-IRES-VEGF165 double-gene co-expression recombination adenovirus; and finally a double-gene recombination adenovirus carrying the VEGAF and the Ang-1 infects vessel endothelial progenitor cells so as to promote the angiogenesis of ischemic myocardium and improve functions of the heart.

A method for identifying the viability of ischemic myocardium of a patient. The method includes the steps of measuring in real-time the ischemic myocardium of a beating or non-beating heart. There is the step of determining in real-time whether the ischemic myocardium of the beating or non-beating heart is stunned or is nonviable. An apparatus for identifying the viability of ischemic myocardium of a patient's heart. The apparatus includes an electrode array having at least four electrodes for electrical communication with the heart which produces an array signal. The apparatus includes a processor portion in communication with the array which receives the array signal and determines in real-time whether the ischemic myocardium of the heart is stunned or is nonviable. An apparatus for analyzing living tissue. The apparatus includes an electrode array having at least four electrodes for electrical communication with the tissue which produces an array signal. The apparatus includes an admittance magnitude and phase detection circuit in communication with the array which receives the array signal from the array and produces a detection circuit signal corresponding to phase angle and magnitude of the array and signal. The apparatus includes a processor in communication with the detection circuit which receives the detection circuit signal and determines permittivity and conductivity of the tissue in real-time. A method for analyzing living tissue.

Methods and apparatus for preventing myocardial infarction, or lessening the size / severity of an evolving myocardial infarction, by cooling at least the affected area of the myocardium using an intravascular heat exchange catheter. The heat exchange catheter may be inserted into the vasculature (e.g., a vein) and advanced to a position wherein a heat exchanger on the catheter is located in or near the heart (e.g., within the vena cava near the patient's heart). Thereafter, the heat exchange catheter is used to cool the myocardium (or the entire body of the patient) to a temperature that effectively lessens the metabolic rate and / or oxygen consumption of the ischemic myocardial cells or otherwise protects the ischemic myocardium from undergoing irreversible damage or infarction.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention discloses an ischemic-myocardium-targeted VEGF (vascular endothelial growth factor) recombinant protein. The invention provides a fusion protein which is composed of a VEGF 165, a targeted polypeptide IMT and a connecting peptide for connecting the VEGF 165 and targeted polypeptide IMT. The experiment proves that the brand-new ischemic-myocardium-targeted VEGF protein IMT-VEGF designed in the invention can be targeted to the infarct zone through intravenous injection so as to increase the VEGF effective local concentration. The ischemic-myocardium-targeted VEGF recombinant protein has wide application prospects in targeted therapy, and can be targeted to the ischemic myocardium tissues through intravenous injection to promote the injury repair and cardiac function restoration.

The invention discloses an application of a morindae officinalis extract and morindae officinalis oligosaccharide pentasaccharide to preparation of a drug for treating myocardial ischemia and / or reperfusion injury and promoting therapeutic angiogenesis. The myocardial ischemia and reperfusion injury belong to secondary injury brought to an organism when the hemoperfusion of myocardium is stopped or poor, i.e., after the myocardium is subjected to ischemia, hypoxia injury, circulation reinstitution and blood supply recovery. The morindae officinalis extract and the morindae officinalis oligosaccharide pentasaccharide both play a role in protecting an in-vivo rat myocardial ischemia reperfusion injury model and an in-vitro purification cultured neonatal rat myocardial cell hypoxia / reoxygenation injury model, and can be used for remarkably reducing the myocardial infarction area and the incidence rate of reperfusion arrhythmias, effectively protecting the form of a myocardial cell and relieving the injury of hypoxia / reoxygenation to the myocardial cell. The therapeutic angiogenesis promotion means that the aims of recovering the blood supply of ischemic myocardium and improving the heart function are achieved through increasing the functional coronary artery branch or side branch under the irritation actions of some methods, including the therapeutic actions of some drugs.

The invention provides a method for improving the survivability of old people mesenchymal stem cells after transplanting. According to the method, mesenchymal stem cells with passage stability obtained from the bone marrow of old people are put into a conventional culture medium in which 0.5mumol / L SRT1720, 5mM NAD+ and 20mM glutamine are added; pretreatment is performed for 24 hours; the obtained and processed mesenchymal stem cells are used for cell transplanting treatment. The method has the beneficial effects that for the SRT1720 pretreatment, the apoptosis of the old people mesenchymal stem cells under the stress condition can be inhibited through inhibiting an exogenous apoptosis path of the old people mesenchymal stem cells; after the transplanting of the mesenchymal stem cells subjected to the SRT1720 pretreatment, the survival rate in the ischemic myocardium is improved; the effect for treating ischemic cardiomyopathy is obviously improved.

An application of the active components extracted from chrysanthemum flower in preparing the medicines in the form of solid or liquid for treating the ischemic heart disease is disclosed.

The invention discloses a medicinal composition for treating coronary disease and a preparation method thereof. The medicinal composition is prepared from musk, bezoar, ginseng extracts, cinnamon, storax, borneol, toad venom, ground beetle and auxiliary materials. The medicinal composition has the effects of activating Yang based on aromatic herbs, inducing resuscitation and relieving pains, and tonifying vital energy and strengthening heart, is used for treating angina pectoris, choking sensation in chest and myocardial infarction caused by myocardial ischemia, and can be used in ischemic myocardium collateral revascularization and medicinal bypass of coronary disease.

The present invention relates to a cardio myopeptidin which is isolated from the hearts of non-human healthy mammals. The molecular weight of the cardio myopeptidin is less than 10000 Dalton, the peptide content thereof being 75%˜90%, the free amino acid content 6%˜15%, the ribonucleic acid content less than 2%, and the deoxyribonucleic acid content less than 7.5%. The present invention further provides a method of producing the cardio myopeptidin and the use thereof in producing pharmaceuticals for treating cardiac disorders, specifically the use in producing pharmaceuticals for treating myocardial ischemic and reperfusion injury. The cardio myopeptidin of the present invention can work directly on myocytes, promoting the repair of injuries caused by various reasons, and providing a new way to relieve ischemic and reperfusion injury, and to promote the repair of injured myocardium.

The invention provides a nano-gene material. The nano-gene material is characterized by comprising a targeting nano-gene substrate, the nano-gene substrate is prepared by amino acid polymer, modified polyethylene glycol and angiotensin II polypeptide, wherein the amino acid polymer and the angiotensin II polypeptide are chemically reacted with modified groups at two ends of the modified polyethylene glycol to produce the targeting nano-gene substrate. The novel nano-gene material provided has targeting to ischemic myocardium and protection for genes, excellent transfection effect and low toxicity.

The invention discloses a method for constructing an ordered ischemic-cardiomyocyte-mitochondria-targeting drug-loading (model drugs such as puerarin, baicalin, and the like respectively can act on ischemic cardiomyocyte mitochondria so as to treat myocardial ischemia reperfusion injury ) nanometer micelle, wherein the method comprises synthesizing a TPP-PEG-PE block copolymer, and preparing an ordered targeting drug-loaded nanometer micelle. According to the present invention, the puerarin drug is precisely delivered to ischemic cardiomyocyte mitochondria by using the ordered targeting drug-loaded nanometer micelle so as to provide the pharmacological effect, wherein the drug carrier is accumulated in the ischemic myocardium at the early stage of the infarct in a targeting manner throughthe EPR effect of the PEG-PE nanometer micelle, and the charge effect of the TPP cation mediates the drug carrier to enter the negatively charged cardiomyocyte mitochondria to deliver the puerarin andother drugs to the ischemic cardiomyocyte mitochondria in stages so as to achieve the precise administration.

The present invention relates to the treatment of coronary heart disease by revascularization therapy, and more particularly to the intramyocardial injection of a pharmaceutical composition comprising a recombinant fibroblast growth factor-1 protein or a fragment of a recombinant fibroblast growth factor-1 protein, optionally, with a physiologic glue for inducing local neoangiogenesis in ischemic myocardium. Methods of producing the recombinant fibroblast growth factor 1 protein and fragments are also disclosed.

The invention belongs to the field of traditional Chinese medicines and particularly relates to a preparation method of total flavonoids of clematis filamentosa Dunn and application of the total flavonoids of clematis filamentosa Dunn to a drug for treating myocardial ischemia. The main technical scheme is as follows: whole dried herbs on the overground part of clematis filamentosa Dunn serving as a traditional Chinese medicine are extracted, chromatographically separated and purified to prepare the total flavonoids of clematis filamentosa Dunn, wherein the purity of the total flavonoids of clematis filamentosa Dunn is more than 85%. In-vitro and in-vivo pharmacological experiments prove that the prepared total flavonoids of clematis filamentosa Dunn can be used for treating myocardial ischemia, reducing blood viscosity and reducing platelet aggregation, and have a certain protecting effect for ischemic myocardium cells and a remarkable myocardial ischemia treating effect. The high-purity total flavonoids of clematis filamentosa Dunn are prepared from clematis filamentosa Dunn medicinal materials serving as raw materials through macroporous resin and silica gel chromatographic coupled separation, the total flavonoids of clematis filamentosa Dunn can be prepared into a preparation such as a tablet, a capsule, a dropping pill and a powder injection by adding auxiliary materials, and the preparation can be applied to treatment of myocardial ischemia diseases such as latent coronary heart disease, angina, myocardial infarction and ischemic cardiomyopathy. The preparation method disclosed by the invention is simple and stable in process and is easily produced in batches.

In the field of biological medicines, a use of prourokinase (proUK) and variants thereof in facilitated percutaneous coronary intervention (PCI) in patients with acute myocardial infarction is provided. The use includes: within 6 hrs after a patient is afflicted with accurate myocardial infarction (AMI), firstly, performing thrombolytic therapy with proUK or variants thereof, and then, performing a PCI operation, to dredge the infarction related artery (IRA) as soon as possible, and re-establish an effective forward blood flow, such that an ischemic myocardium is reperfused. According to the present invention, the facilitated PCI for treatment of AMI with the proUK or variants thereof has an effect superior to that of direct PCI.

The invention relates to application of a heart-invigorating and calming tablet in preparation of medicine for curing heart diseases. A large quantity researches indicate that the heart-invigorating and calming tablet has the effects of dilating coronary arteries, increasing coronary blood-flow volume, reducing myocardial oxygen consumption, protecting ischemic myocardium and the like, and is a relatively effective Chinese patent medicine for curing coronary heart disease and stenocardia.

The present invention discloses a myocardial infarction treating cell preparation, a preparation method and applications thereof, wherein the main components in the cell preparation are CTs and BMSCs. According to the present invention, with the direct intracardiac injection or the interventional intracardiac injection of the cell preparation, by performing cell preparation transplantation on the ischemic area and ischemic margin area of the heart of acute myocardial infarction, the severely damaged cell network formed from CTs in the ischemic myocardium ischemic area can be effectively repaired and regenerated so as to repair the cell structure microenvironment beneficial for the regeneration of the infarcted myocardium, such that the regeneration of the infarcted myocardium is easily achieved; and after the transplantation treatment on the acute myocardial infarction, the effects in the fields of infarction area reducing, myocardial infarction heart cardiac function improving, ischemic myocardium fibrosis improving, ischemic area angiogenesis and marginal area angiogenesis promotion, infarcted heart pathological reconstruction improving and after-myocardial-infarction heart failure incidence reducing are superior to the effect of the current commonly-used separate BMSCs treatment.

The invention relates to an injection agent for protecting ischemic myocardium and a preparation method of the injection. Injection emulsion is prepared from the following raw materials in parts by mass: 1 to 5 parts of N-SAHA (Suberoylanilide Hydroxamic Acid), 0.2 to 12.5 parts of emulsifying agent, 2 to 100 parts of oil for injection, 0.02 to 5 parts of solubilizer, 0.03 to 0.4 part of oleic acid, 0.4 to 12.5 parts of glycerinum and the balance of water for injection. The injection emulsion can be effectively used for increasing local drug concentration of the N-SAHA in lipophilic organs such as angiocarpy and / or tissues before cardiac interventional operation, increasing the bioavailability of the N-SAHA, reducing general side effects of the N-SAHA, realizing effective protection on myocardium under an ischemic or reperfusion injury state and reducing or avoiding the occurrence of myocardial infarction; meanwhile, a new optional dosage form is provided for application of the N-SAHAin treating cancer by the injection emulsion.